Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

References

• Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J Mol Biol. 2007;370(5):887–898. doi: 10.1016/j.jmb.2007.04.065.
   PubMed Web of Science ®Google Scholar
• Edgeworth J, Gorman M, Bennett R, et al. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991;266(12):7706–7713.
   PubMed Web of Science ®Google Scholar
• Romand X, Bernardy C, Nguyen MVC, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691–698. doi: 10.1016/j.jbspin.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Bach M, Moon J, Moore R, et al. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(1):47–56. doi: 10.1002/art.41062.
   PubMed Web of Science ®Google Scholar
• Nordal HH, Brokstad KA, Solheim M, et al. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):3. doi: 10.1186/s13075-016-1201-0.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093–1097. doi: 10.1136/ard.2006.064741.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Fagerhol MK, Wien TN, et al. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178. doi: 10.1186/ar3503.
   PubMed Web of Science ®Google Scholar
• Hurnakova J, Hulejova H, Zavada J, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: a large cohort study. PLoS One. 2017;12(8):e0183420. doi: 10.1371/journal.pone.0183420.
   PubMed Web of Science ®Google Scholar
• Hurnakova J, Zavada J, Hanova P, et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):252. doi: 10.1186/s13075-015-0764-5.
   PubMedGoogle Scholar
• Wang Y, Liang Y. Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Int J Clin Exp Pathol. 2019;12:1009–1014.
   PubMed Web of Science ®Google Scholar
• de Moel EC, Rech J, Mahler M, et al. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res Ther. 2019;21(1):268. doi: 10.1186/s13075-019-2064-y.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275. doi: 10.1186/s13075-018-1764-z.
   PubMed Web of Science ®Google Scholar
• Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505. doi: 10.1136/annrheumdis-2013-203923.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford). 2015;54(12):2239–2243. doi: 10.1093/rheumatology/kev251.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, et al. Serum calprotectin versus Acute-Phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken). 2016;68(7):899–906. doi: 10.1002/acr.22795.
   PubMed Web of Science ®Google Scholar
• Nair SC, Welsing PM, Choi IY, et al. A personalized approach to biological therapy using prediction of clinical response based on MRP8/14 serum complex levels in rheumatoid arthritis patients. PLoS One. 2016;11(3):e0152362. doi: 10.1371/journal.pone.0152362.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin and TNF trough serum levels identify power doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18(1):160. doi: 10.1186/s13075-016-1032-z.
   PubMedGoogle Scholar
• Hammer HB, Ødegård S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150–154. doi: 10.1136/ard.2008.103739.
   PubMed Web of Science ®Google Scholar
• Di Ceglie I, Kruisbergen NNL, van den Bosch MHJ, et al. Fc-gamma receptors and S100A8/A9 cause bone erosion during rheumatoid arthritis. Do they act as partners in crime? Rheumatology (Oxford). 2019;58(8):1331–1343. doi: 10.1093/rheumatology/kez218.
   PubMed Web of Science ®Google Scholar
• Jonsson MK, Sundlisæter NP, Nordal HH, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76(12):2031–2037. doi: 10.1136/annrheumdis-2017-211695.
   PubMed Web of Science ®Google Scholar
• Nordal HH, Fagerhol MK, Halse AK, et al. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2018;78(1-2):102–108. doi: 10.1080/00365513.2017.1419371.
   PubMed Web of Science ®Google Scholar
• Van Hoovels L, Vander Cruyssen B, Bogaert L, et al. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis. Clin Chem Lab Med. 2019;58(1):40–49. doi: 10.1515/cclm-2019-0508.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Bolton-King P, Bakkeheim V, et al. Examination of intra and interrater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(11):1995–1998. doi: 10.1136/ard.2011.152926.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. Arthritis Res Ther. 2011;13(3):R78. doi: 10.1186/ar3341.
   PubMed Web of Science ®Google Scholar
• Haavardsholm EA, Aga A-B, Olsen IC, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016;354:i4205. doi: 10.1136/bmj.i4205.
   PubMedGoogle Scholar
• Hammer HB, Uhlig T, Kvien TK, et al. Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2018;70(5):703–712. doi: 10.1002/acr.23339.
   PubMed Web of Science ®Google Scholar
• Hetland G, Berntzen HB, Fagerhol MK. Levels of calprotectin (leukocyte L1 protein) during apheresis. Scand J Clin Lab Invest. 1992;52(6):479–482. doi: 10.3109/00365519209090124.
   PubMed Web of Science ®Google Scholar
• Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32:2485–2487.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48. doi: 10.1002/art.1780380107.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Jensen Hansen IM, Järvinen P, et al. Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. Rheumatol Adv Pract. 2021;5:rkab030.
   PubMedGoogle Scholar
• Hammer HB, Hansen I, Järvinen P, et al. Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis. Scand J Rheumatol. 2021;50(4):262–270. doi: 10.1080/03009742.2020.1845394.
   PubMed Web of Science ®Google Scholar
• Blavnsfeldt AG, Parkner T, Knudsen CS. Plasma calprotectin - preanalytical stability and interference from hemolysis. Scand J Clin Lab Invest. 2022;82(5):349–355. doi: 10.1080/00365513.2022.2092901.
   PubMed Web of Science ®Google Scholar